Brainsway Ltd ADR (BWAY) Stock Price, Quote & News

Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitatio...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 2 582 4030

Website: www.brainsway.com

Address:

16 Hartum St, Har Hotzvim, Jerusalem, Israel

BEATOFtheMARKET Oct. 24 at 10:52 PM

$BWAY $BVN $BUSE $BULU $BUD 🔥

0 · Reply

BrainsWay Oct. 21 at 11:06 AM

$BWAY BrainsWay’s recent FDA clearance for its accelerated Deep TMS protocol isn’t just a milestone; it’s a turning point. By reducing treatment time from 4 weeks to just 6 days, this breakthrough could reshape how depression is treated and open the door to wider clinical adoption. As clinics, patients, and insurers begin to recognize the impact of this faster, more accessible approach, the commercial potential for Deep TMS continues to grow. #BrainsWay #DeepTMS #FDAApproval #MentalHealth #InvestorNews #Neurotech

0 · Reply

NickBFinanc Oct. 20 at 9:01 PM

Are there other mental health or neurological indications $BWAY is currently studying for Deep TMS?

0 · Reply

BrainsWay Oct. 20 at 9:17 AM

$BWAY Deep TMS Is Redefining Mental Health Treatment Psychiatrist Dr. Muhamad Aly Rifai shares how BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) is delivering real results for patients battling severe depression, OCD, and other treatment-resistant conditions, sometimes in as little as five days. With remission rates up to 79% and a non-invasive, drug-free approach, Deep TMS is rapidly gaining traction as a next-generation solution in the $20B+ global mental health treatment market. As more clinics and providers adopt this technology, BrainsWay stands at the forefront of a major shift in psychiatric care. 🎥 Watch the full interview: youtube.com/watch?v=lJlXpt220ao

0 · Reply

ShelliRew Oct. 17 at 9:03 PM

$BWAY Here is the start to many more good news to come https://www.msn.com/en-us/money/topstocks/brainsway-ltd-announces-successful-outcomes-of-annual-shareholder-meeting/ar-AA1MnCMB?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

1 · Reply

daytrader_dav Oct. 15 at 2:33 PM

$BWAY what was it, $78M in cash? Above 70% in recurring revenues and a 90% retention rate. more should be on this. wild what $BWAY is doing with their technology and sales.

3 · Reply

NickBFinanc Oct. 8 at 6:11 PM

$BWAY I’ve been watching $BWAY for a bit now… the tech they’ve got in mental health is actually underrated. FDA cleared devices treating depression + OCD. Once the market wakes up to how scalable this is, this will jump. If BrainsWay gets more insurance coverage + awareness, this could move way higher from $15.

1 · Reply

BrainsWay Oct. 8 at 4:45 PM

$BWAY Featured in MassDevice: BrainsWay has received expanded FDA clearance for our Deep TMS™ system, now including an accelerated treatment protocol for Major Depressive Disorder (MDD) and patients with comorbid anxiety symptoms. 🔹 6 treatment days vs. 4 weeks under the standard protocol 🔹 Each session lasts less than 10 minutes 🔹 Supported by a multicenter, randomized, controlled study 🔹 Comparable efficacy with fewer clinic visits Read the full MassDevice feature: https://lnkd.in/eHMBefcf

0 · Reply

BrainsWay Oct. 6 at 4:29 PM

$BWAY The global mental health app market is projected to reach $17.5 billion by 2030. At BrainsWay, we believe treatment must be fast, data-driven, and deeply human. Our mission is to equip clinics, providers, and patients with the next generation of solutions. In our latest milestone, we’ve received FDA clearance for the Accelerated Deep TMS Protocol, a breakthrough in non-invasive treatment for Major Depressive Disorder (MDD). And with 4 FDA-cleared indications, MDD, OCD, Anxious Depression, and Smoking Addiction, we are advancing on critical fronts to ensure care evolves with both urgency and technology. 🚀 Our Innovation Pipeline: - Insights Cloud - Data-driven clinical intelligence - TMS 360 - A complete platform for interventional care - AI Personalization - Protocols tailored to every brain - Complementary Home Device - Extending treatment beyond the clinic

0 · Reply

NVDAMillionaire Oct. 3 at 11:01 AM

$BWAY Brilliant piece that captures BWAY's situation perfectly. So if you want to update your understanding of BWAY or get to know BWAY better, this is essential reading. https://beyondspx.com/quote/BWAY/analysis/brainsway-s-deep-dive-into-growth-expanding-reach-and-innovation-in-neurostimulation-nasdaq-bway

0 · Reply

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.

Aug 20, 2025, 7:30 AM EDT - 2 months ago

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

Aug 13, 2025, 3:21 PM EDT - 2 months ago

BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:30 AM EDT - 2 months ago

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights

Jun 11, 2025, 7:30 AM EDT - 4 months ago

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

Jun 10, 2025, 8:00 AM EDT - 4 months ago

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego

Jun 4, 2025, 7:30 AM EDT - 5 months ago

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC

May 13, 2025, 10:16 AM EDT - 5 months ago

BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 5 months ago

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

Mar 11, 2025, 10:17 AM EDT - 8 months ago

BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 8 months ago

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Dec 12, 2024, 8:00 AM EST - 11 months ago

BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

Nov 20, 2024, 8:00 AM EST - 1 year ago

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

Nov 12, 2024, 12:59 PM EST - 1 year ago

BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:30 AM EST - 1 year ago

BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights

Oct 29, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

Oct 9, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea

Sep 30, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners

Sep 16, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces Significant Expansion on U.S. East Coast

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals

Aug 29, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Appoints Richard A. Bermudes, M.D.

Aug 13, 2024, 4:40 AM EDT - 1 year ago

BrainsWay: Operating Leverage Driving Upside

Aug 6, 2024, 12:03 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 23, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 17, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada

Jun 10, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

Jun 3, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression

May 9, 2024, 9:00 AM EDT - 1 year ago

BrainsWay: Cash Flows Are Underappreciated

May 8, 2024, 1:16 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights

Apr 24, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 4, 2024, 8:00 AM EDT - 1 year ago

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

Mar 18, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Mar 6, 2024, 10:04 AM EST - 1 year ago

BrainsWay Ltd. (BWAY) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:30 AM EST - 1 year ago

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Feb 21, 2024, 8:00 AM EST - 1 year ago

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Jan 10, 2024, 7:30 AM EST - 1 year ago

BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology

Dec 19, 2023, 7:30 AM EST - 2 years ago

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

Dec 7, 2023, 8:00 AM EST - 2 years ago

BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea

Nov 20, 2023, 7:30 AM EST - 2 years ago

Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives

Nov 20, 2023, 12:01 AM EST - 2 years ago

BrainsWay: Positive Cash Flow And Continued Growth

Nov 15, 2023, 2:52 PM EST - 2 years ago

Brainsway Ltd (BWAY) Q3 2023 Earnings Call Transcript

Nov 15, 2023, 7:30 AM EST - 2 years ago

BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights

Oct 16, 2023, 7:30 AM EDT - 2 years ago

BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression

Sep 20, 2023, 7:30 AM EDT - 2 years ago

BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie's Way Plus

Sep 5, 2023, 7:30 AM EDT - 2 years ago

BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S.

Aug 23, 2023, 7:30 AM EDT - 2 years ago

BrainsWay Further Expands Access to Deep TMS™ in Asia Pacific Region

Aug 10, 2023, 4:07 PM EDT - 2 years ago

BrainsWay: Profitability Is Within Sight

Aug 9, 2023, 1:29 PM EDT - 2 years ago

Brainsway Ltd (BWAY) Q2 2023 Earnings Call Transcript

BEATOFtheMARKET Oct. 24 at 10:52 PM

$BWAY $BVN $BUSE $BULU $BUD 🔥

0 · Reply

BrainsWay Oct. 21 at 11:06 AM

0 · Reply

NickBFinanc Oct. 20 at 9:01 PM

Are there other mental health or neurological indications $BWAY is currently studying for Deep TMS?

0 · Reply

BrainsWay Oct. 20 at 9:17 AM

0 · Reply

ShelliRew Oct. 17 at 9:03 PM

1 · Reply

daytrader_dav Oct. 15 at 2:33 PM

$BWAY what was it, $78M in cash? Above 70% in recurring revenues and a 90% retention rate. more should be on this. wild what $BWAY is doing with their technology and sales.

3 · Reply

NickBFinanc Oct. 8 at 6:11 PM

1 · Reply

BrainsWay Oct. 8 at 4:45 PM

0 · Reply

BrainsWay Oct. 6 at 4:29 PM

0 · Reply

NVDAMillionaire Oct. 3 at 11:01 AM

0 · Reply

BroadwayBrokers Sep. 28 at 7:33 PM

$BWAY Sales are high and cash flow is strong. Leadership seems legit. FDA approval OTW.

0 · Reply

BrainsWay Sep. 25 at 7:28 PM

$BWAY BrainsWay CEO on FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of MDD “More than just another clearance, this marks a pivotal advancement in the treatment of depression with Deep TMS because it expands the ways in which we can use Deep TMS to treat depression. While previously, treatment involved 4 weeks of daily treatment sessions before follow up visits, this newly cleared accelerated protocol includes an acute phase of just 6 treatment days.” Quote from Hadar Levy, CEO of BrainsWay

1 · Reply

BrainsWay Sep. 18 at 5:01 PM

$BWAY BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD) This breakthrough gives patients a faster and non-invasive pathway to relief with no fMRI neuro-navigation required. We are proud to advance the accessibility of mental health care worldwide. 🔗 Read the full announcement here: https://www.brainsway.com/news_events/brainsway-receives-fda-clearance-for-accelerated-deep-tms-protocol-for-non-invasive-treatment-of-major-depressive-disorder-mdd/ #BrainsWay #BWAY #IR #Neurotech #DeepTMS #Growth

0 · Reply

ZacksResearch Sep. 17 at 5:03 PM

$BWAY surges 11.9% on FDA clearance! 🚀 The new accelerated TMS protocol for depression is a game-changer, reducing treatment time significantly and boosting accessibility. This positions BrainsWay to capture more of the mental health market, driving strong growth potential. Discover the full impact here 👉 https://www.zacks.com/stock/news/2752844/bway-shares-gain-on-fda-nod-for-accelerated-deep-tms-depression-care?cid=sm-stocktwits-2-2752844-body-12865&ADID=SYND_STOCKTWITS_TWEET_2_2752844_BODY_12865

0 · Reply

ZacksResearch Sep. 17 at 4:03 PM

$BWAY popping on FDA green light 🚀🧠 Shares jumped after approval of its accelerated Deep TMS protocol, delivering faster depression care backed by strong clinical results. See the full details here 👉 https://www.zacks.com/stock/news/2752844/bway-shares-gain-on-fda-nod-for-accelerated-deep-tms-depression-care?cid=sm-stocktwits-2-2752844-teaser-12855&ADID=SYND_STOCKTWITS_TWEET_2_2752844_TEASER_12855

0 · Reply

notreload_ai Sep. 16 at 4:13 PM

$BWAY has received FDA clearance for a new Deep TMS protocol, providing a non-invasive treatment for Major Depressive Disorder. This method targets deep brain areas to reduce treatment times. https://notreload.xyz/brainsway-deep-tms-accelerated-depression-treatment-approved/

0 · Reply

OpenOutcrier Sep. 16 at 12:42 PM

$BWAY (+3.0% pre) BrainsWay gets FDA clearance for accelerated depression treatment protocol https://ooc.bz/l/77430

0 · Reply

BrainsWay Sep. 16 at 8:01 AM

$BWAY 📊 BrainsWay by the Numbers: Strong Fundamentals for Growth BrainsWay (NASDAQ: BWAY) continues to advance its leadership in Deep TMS™ with solid financial guidance and a growing clinical and commercial footprint: • ~$52M Revenue (2025 guidance) • 75% Gross Margin (2025 guidance) • $7M Adjusted EBITDA (2025 guidance) • $78M Cash Balance (as of Q2 2025) • $62M Signed Backlog (Q2 2025) • 1,522 Total Installed Base (as of Q2 2025) • 880 OCD Systems (as of Q2 2025) • 6.3M Deep TMS™ Treatments delivered to 220K+ patients • 35+ Completed Clinical Trials with 360+ publications Each new deal BrainsWay has with leading mental health providers has the potential to add $10–15M in RPO with no additional operational expense, accelerating both top-line growth and margins. #BrainsWay #BWAY #InvestorRelations #Neurotech #DeepTMS

0 · Reply

BrainsWay Sep. 10 at 4:17 PM

$BWAY BrainsWay is proud to exhibit at the 25th World Congress of Psychiatry (WCP 2025) in Prague, October 5–8. We’ll showcase our groundbreaking Deep TMS™ technology, advancing mental health treatment for depression, OCD, and addictions worldwide. Come meet us in Prague and discover how BrainsWay is shaping the future of psychiatry. 💡 #WCP2025 #BrainsWay #DeepTMS #MentalHealth

0 · Reply

BrainsWay Sep. 8 at 1:26 PM

$BWAY BrainsWay closed a record-breaking quarter (Q2), reflecting strong demand for our noninvasive neurostimulation tech & commitment to advancing mental health care. Key Highlights: • Revenue: $12.6M, up 26% YoY • EBITDA: +40% YoY in H1 2025 • Net Profit: $2M, up 240% YoY • Performance Obligations: $62M, up 25% YoY • Cash Flow: 8 consecutive quarters of positive free cash flow • Guidance: Raised full-year 2025 Revenue and EBITDA outlook Operational Momentum: • 88 systems shipped in Q2 (+35% YoY); global installed base reached 1,522 systems • ~70% of recent customer engagements structured as multi-year lease agreements Strategic Partnerships: • Completed equity financings with Stella MSO and Axis MSO, two leading clinic networks Innovation Pipeline: • FDA submissions for accelerated MDD & adolescent depression protocols • PTSD expansion through collaboration with the Israel Ministry of Defense to support soldiers • BrainsWay continues to expand access, drive innovation, & lead in Deep TMS tech

0 · Reply

BrainsWay Sep. 4 at 1:33 PM

$BWAY Welcome to the official BrainsWay ($BWAY) Investor Relations profile. Here you’ll find the latest news, financial updates, and official company announcements. We’re committed to keeping our shareholders informed, engaged, and confident in our vision.

0 · Reply

levilovelevi Aug. 25 at 4:48 PM

$BWAY

2 · Reply

Market Cap	319.74M
Revenue (ttm)	41.02M
Net Income (ttm)	2.92M
EPS (ttm)	N/A
PE Ratio	63.96
Forward PE	47.07
Profit Margin	7.12%
Debt to Equity Ratio	0.00

Volume	33,100
Avg Vol	72,330
Day's Range	N/A - N/A
Shares Out	19.00M
Stochastic %K	95%
Beta	1.23
Analysts	Strong Sell
Price Target	$18.20